Skip to content

Clinical trials

Muscular Dystrophies trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Muscular Dystrophies Country / region: Italy Clear all

31 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20102
20112
20122
20132
20141
20161
20173
20185
20213
20222
20232
20241
20251
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Terminated6
Recruiting5
Active, not recruiting4
Unknown status2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
IRCCS Eugenio Medea4
Cooperative International Neuromuscular Research Group2
GlaxoSmithKline2
PTC Therapeutics2
Sarepta Therapeutics, Inc.2
Alessandra Pedrocchi1
Avidity Biosciences, Inc.1
BioMarin Pharmaceutical1
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Muscular Dystrophies31
Muscular Dystrophy, Duchenne18
Neuromuscular Diseases9
Muscular Diseases7
Musculoskeletal Diseases6
Genetic Diseases, Inborn5
Muscular Disorders, Atrophic5
Nervous System Diseases5
Muscular Dystrophy, Facioscapulohumeral4
Genetic Diseases, X-Linked3

Trials

Showing 76 to 31 of 31. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.